EMERYVILLE, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , a specialty biopharmaceutical company, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed public offering of up to $65 million of its common stock. Proceeds from the offering will be used primarily to fund the ongoing clinical development of Viprinex(TM) (ancrod). All of the shares in the proposed offering are being sold by the Company.
Merriman Curhan Ford & Co. will act as underwriter and book-running manager for the proposed offering. This offering will be made only by means of a prospectus. When available, copies of the prospectus relating to these securities may be obtained from: Merriman Curhan Ford & Co., 600 California Street, 9th Floor, San Francisco, CA 94108, Telephone 415-248-5600, Fax 415-248-5690.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Neurobiological Technologies, Inc.
NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late- stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.
Neurobiological Technologies, Inc.
CONTACT: Craig W. Carlson, Vice President and Chief Financial Officer ofNeurobiological Technologies, Inc., +1-510-595-6000
Web site: http://www.ntii.com/
